These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 28548198)

  • 41. SGLT2 Inhibitors and Euglycemic Ketoacidosis.
    Masuta P; Johri G; Paul M
    Am J Ther; 2018; 25(4):e498-e500. PubMed ID: 28537992
    [No Abstract]   [Full Text] [Related]  

  • 42. [Not Available].
    Shamchuk A; Doulla M; Jetha M
    CMAJ; 2021 Nov; 193(45):E1746-E1749. PubMed ID: 34782384
    [No Abstract]   [Full Text] [Related]  

  • 43. Life-threatening hyperglycemia and acidosis related to olanzapine: a case report and review of the literature.
    Varma MK; Connolly K; Fulton B
    J Intensive Care Med; 2007; 22(1):52-5. PubMed ID: 17259569
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus.
    Rosenthal N; Meininger G; Ways K; Polidori D; Desai M; Qiu R; Alba M; Vercruysse F; Balis D; Shaw W; Edwards R; Bull S; Di Prospero N; Sha S; Rothenberg P; Canovatchel W; Demarest K
    Ann N Y Acad Sci; 2015 Nov; 1358():28-43. PubMed ID: 26305874
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Canagliflozin use in Type I diabetes mellitus.
    Guthrie R
    Postgrad Med; 2017 Apr; 129(3):336-339. PubMed ID: 27918226
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Euglycemic diabetic ketoacidosis caused by dapagliflozin: A case report.
    Chou YM; Seak CJ; Goh ZNL; Seak JC; Seak CK; Lin CC
    Medicine (Baltimore); 2018 Jun; 97(25):e11056. PubMed ID: 29923997
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Altered Patterns of Early Metabolic Decompensation in Type 1 Diabetes During Treatment with a SGLT2 Inhibitor: An Insulin Pump Suspension Study.
    Patel NS; Van Name MA; Cengiz E; Carria LR; Weinzimer SA; Tamborlane WV; Sherr JL
    Diabetes Technol Ther; 2017 Nov; 19(11):618-622. PubMed ID: 29068709
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Insights Into the Recognition and Management of SGLT2-Inhibitor-Associated Ketoacidosis: It's Not Just Euglycemic Diabetic Ketoacidosis.
    Dizon S; Keely EJ; Malcolm J; Arnaout A
    Can J Diabetes; 2017 Oct; 41(5):499-503. PubMed ID: 28797889
    [No Abstract]   [Full Text] [Related]  

  • 49. Metabolic Acidosis in Postsurgical Patient on Canagliflozin and Metformin: A Case Report.
    Darwish AM
    A A Pract; 2019 Apr; 12(7):221-222. PubMed ID: 30234515
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Euglycemic Diabetic Ketoacidosis: Hidden in Plain Sight.
    Crespo L; McConnell B; Wick JY
    Consult Pharm; 2016; 31(8):426-34. PubMed ID: 27535077
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Canagliflozin use in patients with renal impairment-Utility of quantitative clinical pharmacology analyses in dose optimization.
    Khurana M; Vaidyanathan J; Marathe A; Mehrotra N; Sahajwalla CG; Zineh I; Jain L
    J Clin Pharmacol; 2015 Jun; 55(6):647-56. PubMed ID: 25612234
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors.
    Ogawa W; Sakaguchi K
    J Diabetes Investig; 2016 Mar; 7(2):135-8. PubMed ID: 27042263
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Euglycaemic diabetic ketoacidosis in bariatric surgery patients with type 2 diabetes taking canagliflozin.
    van Niekerk C; Wallace J; Takata M; Yu R
    BMJ Case Rep; 2018 Aug; 2018():. PubMed ID: 30131409
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Euglycemic ketosis in an adolescent with type 1 diabetes on insulin and dapaglifozin: Case report].
    Pereyra A M; Ramírez C; Román R
    Rev Chil Pediatr; 2017 Jun; 88(3):404-410. PubMed ID: 28737202
    [TBL] [Abstract][Full Text] [Related]  

  • 55. When Guidelines Fail: Euglycemic Diabetic Ketoacidosis After Bariatric Surgery in a Patient Taking a Sodium-Glucose Cotransporter-2 Inhibitor: A Case Report.
    Lane S; Paskar D; Hamed S; Goffi A
    A A Pract; 2018 Jul; 11(2):46-48. PubMed ID: 29634546
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A Case of Euglycemic Diabetic Ketoacidosis due to Empagliflozin Use in a Patient with Type 1 Diabetes Mellitus.
    Bilgin S; Duman TT; Kurtkulagi O; Yilmaz F; Aktas G
    J Coll Physicians Surg Pak; 2022 Jul; 32(7):928-930. PubMed ID: 35795946
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sodium-glucose cotransporter-2-induced euglycemic diabetic ketoacidosis unmasks latent autoimmune diabetes in a patient misdiagnosed with type 2 diabetes mellitus: a case report.
    Vadasz B; Arazi M; Shukha Y; Koren O; Taher R
    J Med Case Rep; 2021 Feb; 15(1):62. PubMed ID: 33581735
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results.
    Usiskin K; Kline I; Fung A; Mayer C; Meininger G
    Postgrad Med; 2014 May; 126(3):16-34. PubMed ID: 24918789
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An Unusual Case of Metabolic Acidosis: Clinical Case Education.
    Abu-Amer N; Dinour D; Mini S; Beckerman P
    Isr Med Assoc J; 2019 Nov; 21(11):766-768. PubMed ID: 31713370
    [No Abstract]   [Full Text] [Related]  

  • 60. Fanconi syndrome associated with SGLT2 inhibitor, canagliflozin.
    Esprit DH; Koratala A
    Nephrology (Carlton); 2018 May; 23(5):493. PubMed ID: 29696765
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.